CD19 and diffuse large B-cell lymphoma: Recently, the L-MIND study investigated len in combination with the anti-CD19 monoclonal antibody tafasitamab for patients with R/R DLBCL; again, thew hematologic and infectious side-effect profile seen was similar to that for the combination of obinutuzumab, HDMP, and len [26].